RecruitingPhase 1NCT06760364
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
21 participants
Start Date
Dec 25, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria8
- Ability to understand and sign a written informed consent documen；
- At the date of signing ICF, 18 \~70 years old, male or female；
- Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
- Positive mesothelin expression;
- At least one measurable lesion at baseline per RECIST version 1.1；
- The expected survival time is more than 12 weeks;
- ECOG 0-1 points;
- Adequate organ functions.
Interventions
DRUGCHT102
CHT 102 : MSLN UCAR-T.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06760364
Related Trials
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
NCT073261371 location
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT050981971 location
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
NCT067704392 locations